微信公众号

请长按图片识别二维码

模型资源

首页 模型资源 细胞资源 CT26-hCD39-LZ

Design of the CT26-hCD39-LZ cell line

The CT26-hCD39-LZ clonal cell line expresses high levels of a human/mouse chimeric CD39, and forms solid tumors in vivo. An optimized version of a luciferase-ZsGreen (LZ) fusion protein is also stably expressed for in vivo imaging and ex vivo tracking.

This cell line can be used in syngeneic models with our huCD39 mouse model.

‍

CT26-hCD39-LZ features

  • Express a functional chimeric CD39 with a fully humanized extracellular domain
  • Express a luciferase-ZsGreen (LZ) fusion reporter
  • Form solid tumors upon subcutaneous injection in fully immunocompetent mice
  • Injected cells can be followed in vivo and ex vivo with our LZ reporter

  • CT26-hCD39-LZ cells homogeneously express chimeric CD39 in vitro

    Expression analysis by flow cytometry. Chimeric CD39 is detected with anti-human CD39 (Biolegend clone A1).

     

  • CT26-hCD39-LZ cells form tumors in vivo

    hCD39 Balb/c mice were injected (s.c.) with 1x106 CT26-chimCD39-LZ cells. Tumor growth was measured every 2 to 3 days. Tumor size (mm3) = (width2 x length)/2.

Commentaries

  1. Development of a new hSIRPα-specific radiotracer for non-invasive PET imaging using genOway’s double humanized hCD47/hSIRPα mouse and MC38-hPD-L1-hCD47-LZ cell line
  2. CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity
  3. A new promising family of small molecules regulating the PD-L1/PD-1 signaling pathway
  4. Improving in vitro models: the coming of age of organoids
  5. iPS technology: Four factors that will change the world… some day

Scientific articles

  1. Two birds with one stone: human SIRPα nanobodies for functional modulation and in vivo imaging of myeloid cells
  2. CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity
  3. ERα-36 regulates progesterone receptor activity in breast cancer
  4. T-cells expressing a chimeric-PD1-Dap10-CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer
  5. Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF
  6. SDHA gain-of-function engages inflammatory mitochondrial retrograde signaling via KEAP1-Nrf2